rttnews.com
Cure8 news brief
AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings At ACG 2026
Medications
Risankizumab
Upadacitinib
IL-23 inhibitor
JAK inhibitor
Fistula
Conference Abstract
Adult patients
Why This Matters
New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.
Who Should Pay Attention
Adults with Crohn's disease or ulcerative colitis (especially those on or considering biologics/JAK inhibitors), gastroenterologists, and IBD researchers.
Study Snapshot
Story typeResearch news
Evidence typeConference abstract
Source depthFull source text
What To Know
AbbVie reported AFFIRM Phase 3 induction data for risankizumab in advanced therapy–naïve Crohn's disease and long-term findings from FORTIFY and SEQUENCE open‑label extension studies showing sustained clinical and endoscopic outcomes through multiple years of treatment.
The company also shared real‑world analyses for upadacitinib (RINVOQ) in difficult‑to‑treat Crohn's populations (fistulizing, stricturing, isolated ileal disease) reporting clinical and endoscopic response/remission rates in treated cohorts.
Keep In Mind
The article reports company announcements and conference abstracts; peer‑reviewed publications or full trial reports are needed to fully evaluate efficacy and safety claims.
Source Details
Review the original publication for the complete reporting, methods, and context.
Conference abstract
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationrttnews.com
AuthorsGayathry Prakash
Indexed viaGoogle News
Source typeWeb article
PublishedOct 12, 2026, 5:38 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate ...
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.